A Phase 3 interventional study of Romosozumab 90 mg/mL and Placebo 90 mg/mL in Postmenopausal Osteoporosis, sponsored by Amgen. Completed at 12 sites in 3 countries. Open to female participants aged 55 Years to 90 Years. Per ClinicalTrials.gov, last updated 2018-11-08.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing romosozumab in Osteoporosis, Postmenopausal — 1 open to participants now, 2 under way, none of them phase 3. romosozumab · Osteoporosis, Postmenopausal.
Among the 12 studies testing romosozumab in Osteoporosis, Postmenopausal, this one is the 5th largest by enrollment, is one of 2 that started in 2013, is one of 6 in phase 3, and was the 6th registered.
334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.
Browse Osteoporosis, Postmenopausal studies →1 of the 12 studies testing romosozumab in Osteoporosis, Postmenopausal is open now. Recruiting first, the newest first:
Massachusetts General Hospital
Ages 45+ · Women only
romosozumab: first FDA approval 2019 (EVENITY), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 19 Osteoporosis, Postmenopausal studies recruiting now, 8 (42%) set no upper age limit and 7 (37%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.
This study: 55 Years to 90 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 2 started in 2013.
This study's enrollment of 294 is above the median of 119 across 264 interventional studies indexed under Osteoporosis, Postmenopausal.
Median enrollment 268 across the 12 interventional studies. Of the 9 that completed or were terminated, 9 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 12 have an industry lead sponsor. The 4 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
24 studies in Osteoporosis, Postmenopausal by Amgen: none open now, none under way, none of them phase 3. Of 24 finished, 23 (96%) have results posted.
Among the 24 studies in Osteoporosis, Postmenopausal by Amgen, this one is the 13th largest by enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2013, is one of 14 in phase 3, and was the 19th registered.
Amgen’s Osteoporosis, Postmenopausal studies by the year they started, since 2004.
1 of the studies testing romosozumab in Osteoporosis, Postmenopausal that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05058976Susan L. GreenspanRomosozumab Use to Build Skeletal Integrity | 2027-03-31 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing romosozumab in Osteoporosis, Postmenopausal, from their registry updates:
Among Amgen’s 24 in Osteoporosis, Postmenopausal:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare 2 formulations of romosozumab (AMG 785) on bone mineral density (BMD) in postmenopausal women with osteoporosis.
Upon confirmation of eligibility, participants were randomized in a 22:5:22:5 ratio to the following treatment groups:
After completing a 6-month treatment period, participants entered a 3-month follow-up period with an end of study (EOS) at month 9.
For the analysis of efficacy endpoints, the 2 placebo groups were combined into a single placebo group. For safety analyses, the data for placebo were presented separately for each group.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
women with osteoporosis at high risk for fracture defined as
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 210 mg romosozumab monthly, administered as 2 subcutaneous (SC) 1.17 mL injections of a 90 mg/mL solution, for 6 months.
Drug: Romosozumab 90 mg/mL
Participants received matching placebo administered as 2 subcutaneous injections of 1.17 mL every month for 6 months.
Drug: Placebo 90 mg/mL
Participants received 210 mg romosozumab monthly, administered as 3 subcutaneous 1.0 mL injections of a 70 mg/mL solution, for 6 months.
Drug: Romosozumab 70 mg/mL
Participants received matching placebo administered as 3 subcutaneous injections of 1.0 mL every month for 6 months.
Drug: Placebo 70 mg/mL
Drug page: Romosozumab
Administered as 2 SC injections of a 90 mg/mL concentration in a 1.17 mL crystal zenith resin prefilled syringe (PFS).
Also known as: AMG 785, EVENITY™
Placebo administered as 2 SC injections with the 1.17 mL crystal zenith resin PFS.
Drug page: Romosozumab
Administered as 3 SC injections of a 70 mg/mL concentration in a 1.0 mL glass PFS.
Also known as: AMG 785, EVENITY™
Placebo administered as 3 SC injections with the 1.0 mL glass PFS.
Percent Change From Baseline in Bone Mineral Density (BMD) at the Lumbar Spine
Bone mineral density was measured by dual-energy X-ray absorptiometry (DXA).
Time frame: Baseline and month 6
Percent Change From Baseline in Total Hip BMD
Total hip BMD was measured using DXA. The analysis was based on an ANCOVA model adjusted for treatment and baseline total hip BMD T-score.
Time frame: Baseline and month 6
Percent Change From Baseline in Femoral Neck BMD
Femoral neck BMD was measured using DXA. The analysis was based on an ANCOVA model adjusted for treatment and baseline femoral neck BMD T-score.
Time frame: Baseline and month 6
Percent Change From Baseline in N-Terminal Propeptide Type 1 Procollagen (P1NP)
Time frame: Baseline, month 1, month 3, and month 6
Percent Change From Baseline in Serum C-Telopeptide (CTX)
Time frame: Baseline, month 1, month 3, and month 6
This study was conducted at 11 centers: 7 in Poland, 2 in the Czech Republic, and 2 in the United States. The first participant enrolled on 03 December 2013 and the last participant enrolled on 07 March 2014.
| Milestone | Placebo | Romosozumab 70 mg/mL | Romosozumab 90 mg/mL |
|---|---|---|---|
| Started | 53 | 118 | 123 |
| Received study treatment | 53 | 118 | 123 |
| Completed | 47 | 110 | 117 |
| Not completed | 6 | 8 | 6 |
| Withdrew: Withdrawal by subject | 5 | 5 | 5 |
| Withdrew: Protocol-specified criteria | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 2 | 1 |
Bone mineral density was measured by dual-energy X-ray absorptiometry (DXA).
| percent change | Placebo | Romosozumab 70 mg/mL | Romosozumab 90 mg/mL |
|---|---|---|---|
| Percent Change From Baseline in Bone Mineral Density (BMD) at the Lumbar Spine | 0.8 (-0.4 to 2.1) | 9.6 (8.8 to 10.4) | 9.2 (8.4 to 10.0) |
Total hip BMD was measured using DXA. The analysis was based on an ANCOVA model adjusted for treatment and baseline total hip BMD T-score.
| percent change | Placebo | Romosozumab 70 mg/mL | Romosozumab 90 mg/mL |
|---|---|---|---|
| Percent Change From Baseline in Total Hip BMD | -0.0 (-0.9 to 0.8) | 3.9 (3.4 to 4.4) | 3.4 (2.9 to 4.0) |
Femoral neck BMD was measured using DXA. The analysis was based on an ANCOVA model adjusted for treatment and baseline femoral neck BMD T-score.
| percent change | Placebo | Romosozumab 70 mg/mL | Romosozumab 90 mg/mL |
|---|---|---|---|
| Percent Change From Baseline in Femoral Neck BMD | -0.5 (-1.5 to 0.5) | 3.1 (2.5 to 3.8) | 2.6 (2.0 to 3.3) |
| percent change | Placebo | Romosozumab 70 mg/mL | Romosozumab 90 mg/mL |
|---|---|---|---|
| Month 1 | 2.000 (-5.797 to 16.129) | 96.296 (67.143 to 159.341) | 97.435 (69.259 to 126.179) |
| Month 3 | -9.601 (-21.503 to 2.922) | 23.960 (-1.587 to 46.667) | 16.216 (-10.390 to 50.000) |
| Month 6 | -12.500 (-27.500 to 14.286) | -2.885 (-28.070 to 18.421) | -3.604 (-22.222 to 27.273) |
| percent change | Placebo | Romosozumab 70 mg/mL | Romosozumab 90 mg/mL |
|---|---|---|---|
| Month 1 | 0.282 (-16.183 to 12.874) | -23.158 (-42.943 to -9.967) | -21.456 (-35.602 to -7.246) |
| Month 3 | -5.687 (-20.666 to 15.566) | -11.219 (-35.206 to 9.484) | -5.473 (-24.139 to 26.386) |
| Month 6 | -8.120 (-26.935 to 10.059) | -25.780 (-43.573 to -8.216) | -17.305 (-37.566 to 6.405) |
Collected over Adverse events are reported from the first dose of study drug until 90 days after last dose (9 months overall).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo 70 mg | — | 4/26 (15.4%) | 9/26 (34.6%) |
| Placebo 90 mg/mL | — | 2/26 (7.7%) | 5/26 (19.2%) |
| Romosozumab 70 mg/mL | — | 7/119 (5.9%) | 24/119 (20.2%) |
| Romosozumab 90 mg/mL | — | 3/123 (2.4%) | 38/123 (30.9%) |
| Event | Placebo 70 mg | Placebo 90 mg/mL | Romosozumab 70 mg/mL | Romosozumab 90 mg/mL |
|---|---|---|---|---|
| Mesenteric artery embolismGastrointestinal disorders | 1/26 | 0/26 | 0/119 | 0/123 |
| DeathGeneral disorders | 1/26 | 0/26 | 0/119 | 0/123 |
| Humerus fractureInjury, poisoning and procedural complications | 0/26 | 1/26 | 0/119 | 0/123 |
| Patella fractureInjury, poisoning and procedural complications | 1/26 | 0/26 | 0/119 | 0/123 |
| Spinal deformityMusculoskeletal and connective tissue disorders | 0/26 | 1/26 | 0/119 | 0/123 |
| Spinal osteoarthritisMusculoskeletal and connective tissue disorders | 0/26 | 1/26 | 0/119 | 0/123 |
| Vertebral lesionMusculoskeletal and connective tissue disorders | 0/26 | 1/26 | 0/119 | 0/123 |
| Adenocarcinoma of colonNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/26 | 0/26 | 0/119 | 0/123 |
| Medullary thyroid cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/26 | 0/26 | 0/119 | 0/123 |
| PolyneuropathyNervous system disorders | 0/26 | 1/26 | 0/119 | 0/123 |
| Event | Placebo 70 mg | Placebo 90 mg/mL | Romosozumab 70 mg/mL | Romosozumab 90 mg/mL |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 3/26 | 0/26 | 9/119 | 19/123 |
| HeadacheNervous system disorders | 3/26 | 0/26 | 2/119 | 2/123 |
| AstheniaGeneral disorders | 0/26 | 2/26 | 4/119 | 4/123 |
| Upper respiratory tract infectionInfections and infestations | 1/26 | 2/26 | 1/119 | 2/123 |
| FallInjury, poisoning and procedural complications | 2/26 | 0/26 | 2/119 | 2/123 |
| Bone painMusculoskeletal and connective tissue disorders | 0/26 | 2/26 | 2/119 | 2/123 |
| Injection site painGeneral disorders | 0/26 | 0/26 | 7/119 | 3/123 |
| Injection site erythemaGeneral disorders | 0/26 | 0/26 | 2/119 | 7/123 |
| Urinary tract infectionInfections and infestations | 0/26 | 1/26 | 1/119 | 7/123 |
All randomized participants (full analysis set)
| Age, Continuous(years) | Placebo | Romosozumab 70 mg/mL | Romosozumab 90 mg/mL | Total |
|---|---|---|---|---|
| Mean | 68.4 ± 8.0 | 67.4 ± 7.1 | 67.7 ± 7.6 | 67.7 ± 7.5 |
| Age, Customized(Participants) | Placebo | Romosozumab 70 mg/mL | Romosozumab 90 mg/mL | Total |
|---|---|---|---|---|
| < 65 years | 23 | 46 | 46 | 115 |
| ≥ 65 years | 30 | 72 | 77 | 179 |
| Sex: Female, Male(Participants) | Placebo | Romosozumab 70 mg/mL | Romosozumab 90 mg/mL | Total |
|---|---|---|---|---|
| Female | 53 | 118 | 123 | 294 |
| Male | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Romosozumab 70 mg/mL | Romosozumab 90 mg/mL | Total |
|---|---|---|---|---|
| Hispanic or Latino | 2 | 6 | 9 | 17 |
| Not Hispanic or Latino | 51 | 112 | 114 | 277 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Placebo | Romosozumab 70 mg/mL | Romosozumab 90 mg/mL | Total |
|---|---|---|---|---|
| Asian | 0 | 2 | 0 | 2 |
| Black (or African American) | 0 | 1 | 0 | 1 |
| White | 53 | 115 | 123 | 291 |
| Lumbar Spine Bone Mineral Density (BMD) T-score(T-score) | Placebo | Romosozumab 70 mg/mL | Romosozumab 90 mg/mL | Total |
|---|---|---|---|---|
| Mean | -2.842 ± 1.033 | -2.965 ± 0.960 | -3.029 ± 0.687 | -2.970 ± 0.871 |
| Total Hip BMD T-score(T-score) | Placebo | Romosozumab 70 mg/mL | Romosozumab 90 mg/mL | Total |
|---|---|---|---|---|
| Mean | -2.057 ± 0.634 | -1.819 ± 0.673 | -1.828 ± 0.649 | -1.866 ± 0.660 |
| Femoral Neck BMD T-score(T-score) | Placebo | Romosozumab 70 mg/mL | Romosozumab 90 mg/mL | Total |
|---|---|---|---|---|
| Mean | -2.304 ± 0.517 | -2.139 ± 0.611 | -2.018 ± 0.593 | -2.118 ± 0.595 |
2 further baseline measures are reported on the registry.
Ran from Dec 2013 to primary completion in Sep 2014, 9 months.
Results were first posted in Nov 2018, 4 years 2 months after primary completion. A results delay was requested in Jun 2015.
Of 29 industry-sponsored phase 3 interventional studies under Osteoporosis, Postmenopausal, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 43. This study's 9 months is below that.
Counting every sponsor, half of 30 studies reached it within 24 months; a quarter within 20 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Romosozumab
Osteoporosis, Postmenopausal →